Interactions Between Vitamin D and Androgen Receptor Signaling in Prostate Cancer Cells

Nutrition Reviews

Volumn 65, Issue SUPPL.2, 2007, Pages

  Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; CALCITRIOL RECEPTOR; VITAMIN D;

CELL CULTURE; DRUG EFFECT; DRUG INTERACTION; HUMAN; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVIEW; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; DRUG INTERACTIONS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VITAMIN D;

EID: 35148823144     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2007.tb00336.x     Document Type: Article

References (17)

1. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anti-cancer Res 1990;10:S1307-S1312.
2. John EM, Schwartz GG, Koo J., Van Den Berg D., Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 2005;65:S5470-S5479.
3. Ahonen MH, Tenkanen L., Teppo L., Hakama M., Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11:S847-S852.
4. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1, 25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:S1952-S1960.
5. Miller GJ, Stapleton GE, Ferrara JA, et al. The human prostatic carcinoma cell line NCaP expresses biologically active, specific receptors for 1 alpha, 25-dihydroxyvitamin D3. Cancer Res 1992;52:S515-S520.
6. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1, 25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54:S805-S810.
7. Kobayashi T., Hashimoto K., Yoshikawa K. Growth inhibition of human keratinocytes by 1, 25-dihydroxyvitamin D3 is linked to dephosporylation of retinoblastoma gene product. Biochem Biophys Res Commun 1993;196:S487-S493.
8. Blutt SE, Allegretto EA, Pike JW, Weigel NL 1, 25-dihydroxyvitamin D3 and 9-cis-retinoic acid act syn-ergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 1997;138:S1491-S1497.
9. Campbell MJ, Elstner E., Holden S., Uskokovic M., Koeffler HP. Inhibition of proliferation of prostate cancer cells by a 19-NOR-hexafluoride vitamin D3 analogue involves the induction of p21 (WAF1), p27 (KIP1) and E-cadherin. J Mol Endocrinol 1997;19:S15-S27.
10. Jensen SS, Madsen MW, Lukas J., Binderup L., Bartek J. Inhibitory effects of 1 alpha, 25-dihy-droxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 2001;15:S1370-S1380.
11. Seol JG, Park WH, Kim ES, et al. Effect of a novel vitamin D3 analog, EB1089, on G1 cell cycle regulatory proteins in HL-60 cells. Int J Oncol 2000;16:S315-S320.
12. Blutt SE, McDonnell TJ, Polek TC, Weigel NL Cal-citriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000;141:S10-S17.
13. Guzey M., Kitada S., Reed JC. Apoptosis induction by 1alpha, 25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002;1:S667-S677.
14. Sung V., Feldman D. 1, 25-dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 2000;164:S133-S143.
15. Bao B-Y, Yeh S-D, Lee Y-F. 1a, 25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006;27:S32-S42.
16. Murthy S., Agoulnik IU, Weigel NL. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate 2005;64:S362-S372.
17. Zhao X-Y, Ly LH, Peehl DM, Feldman D. 1a, 25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 1997;138:S3290-S3298.